Article in Press
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Fecha
2011Autor
García-Salcedo, R.
Gonzalez, T.
Moreno, C.
Quiros, I.
Institución
Resumen
In this paper we show, through the study of concrete examples, that depending on the cosmic dynamics of the energy density of matter degrees of freedom living in the brane, Randall-Sundrum (RS) brane effects can be important not only at short distances (UV regime), but also at large cosmological scales (IR regime). Our first example relies on the study, by means of the dynamical system tools, of a toy model based in a nonlinear electrodynamics (NLED) Lagrangian. Then we show that other, less elaborated models, such as the inclusion of a scalar phantom field, and of a tachyon phantom field - trapped in the brane - produce similar results. The form of the RS correction seems to convert what would have been future attractors in general relativity into saddle points. The above 'mixing of scales' effect is distinctive only of theories that modify the right-hand side (matter part) of the Friedmann equation, so that, for instance, Dvali-Gabadadze-Porrati-brane models do not show this feature. " 2011 IOP Publishing Ltd.",,,,,,"10.1088/0264-9381/28/10/105017",,,"http://hdl.handle.net/20.500.12104/44053","http://www.scopus.com/inward/record.url?eid=2-s2.0-79957491164&partnerID=40&md5=e01a7b03f5ecfca61c1dfe23baefb39e",,,,,,"10",,"Classical and Quantum Gravity",,,,"28",,"Scopus WOS",,,,,,,,,,,,"Randall-Sundrum brane cosmology: Modification of late-time cosmic dynamics by exotic matter",,"Article"
"45827","123456789/35008",,,,"Pedroza Zapata, Alvaro Rafael",,"1999",,,,,,,,,,"0187-7674","http://hdl.handle.net/20.500.12104/44048",,,"Español",,,,"66",,"Confines de relaciones internacionales y ciencia política",,"oct-15",,"11",,"CLASE",,,,,,,,"Tecnología",,,,"Gestión estratégica de la tecnología",,"journalArticle"
"45834","123456789/35008",,"Feld, J.J., Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, Toronto, ON, Canada; Jacobson, I.M., Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA; Jensen, D.M., Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA; Foster, G.R., Queen Mary, University of London, Institute of Cellular and Molecular Sciences, London, UK; Pol, S., Hospital Cochin, Université Paris Descartes and INSERM U1610, Paris, France; Tam, E., LAIR Centre, Vancouver, BC, Canada; Jablkowski, M., Medical University of Lodz, Lodz, Poland; Berak, H., Hospital of Infectious Diseases, Warsaw, Poland; Vierling, J.M., Baylor College of Medicine, Houston, TX, USA; Yoshida, E.M., University of British Columbia, Vancouver, BC, Canada; Perez-Gomez, H.R., Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa, Universidad de Guadalajara, Guadalajara, Mexico; Scalori, A., Roche Products Ltd, Welwyn, UK; Hooper, G.J., Roche Products Ltd, Welwyn, UK; Tavel, J.A., Genentech, South San Francisco, CA, USA; Navarro, M.T., Genentech, South San Francisco, CA, USA; Shahdad, S., Roche Products Ltd, Welwyn, UK; Kulkarni, R., Genentech, South San Francisco, CA, USA; Pogam, S.L., Hoffmann-La Roche Inc, Nutley, NJ, USA; Nájera, I., F. Hoffmann-La Roche Ltd, Basel, Switzerland; Eng, S., Genentech, South San Francisco, CA, USA; Lim, C.Y., Genentech, South San Francisco, CA, USA; Shulman, N.S., Genentech, South San Francisco, CA, USA; Yetzer, E.S., Genentech, South San Francisco, CA, USA",,"Feld, J.J. Jacobson, I.M. Jensen, D.M. Foster, G.R. Pol, S. Tam, E. Jablkowski, M. Berak, H. Vierling, J.M. Yoshida, E.M. Perez-Gomez, H.R. Scalori, A. Hooper, G.J. Tavel, J.A. Navarro, M.T. Shahdad, S. Kulkarni, R. Pogam, S.L. Najera, I. Eng, S. Lim, C.Y. Shulman, N.S. Yetzer, E.S.",,"2014",,"Background & Aims: Chronic hepatitis C treatment for prior non-responders to peginterferon (PegIFN)/ribavirin remains suboptimal. The MATTERHORN study evaluated regimens containing ritonavir-boosted danoprevir (danoprevir/r) in prior PegIFN alfa/ribavirin non-responders. Methods: Prior partial responders (N = 152) were randomized to 24. weeks of twice-daily danoprevir/r 100/100. mg, mericitabine 1000. mg and ribavirin 1000/1200. mg (IFN-free); danoprevir/r plus PegIFN alfa-2a/ribavirin (triple); or danoprevir/r, mericitabine and PegIFN alfa-2a/ribavirin (Quad). Prior null responders (N = 229) were randomized to 24. weeks of IFN-free therapy, or quad alone (Quad 24) or quad plus 24-weeks of PegIFN alfa-2a/ribavirin (Quad 48). The primary endpoint was sustained virological response (HCV RNA <25. IU/ml) 24. weeks after end-of-treatment (SVR24). Due to high relapse rates, genotype (G) 1a patients in IFN-free arms were offered additional PegIFN alfa-2a/ribavirin. Results: Among prior partial responders, SVR24 rates were 46.2%, 51.0%, and 86.0%, in the IFN-free, Triple and Quad arms, respectively; among prior null responders, SVR24 rates were 45.5%, 80.5%, and 83.8% respectively. Relapse rates were lower and SVR24 rates higher in G1b-infected than G1a-infected patients. SVR24 rates in G1a and G1b patients randomized to Quad were 75.0% and 96.2%, respectively, in the partial Quad arm, and 68.1% and 100%, respectively, in the null Quad 24 arm. Treatment failure was associated with resistance to danoprevir, but not to mericitabine, and was more common in G1a infected patients. Treatment was well-tolerated. Conclusions: Danoprevir/r, mericitabine plus PegIFN alfa-2a/ribavirin was well-tolerated and produced high overall SVR24 rates in prior partial and null responders to PegIFN alfa/ribavirin. In contrast, IFN-free regimens were associated with unacceptably high relapse rates. " 2014 European Association for the Study of the Liver.